Kura Oncology Inc (NASDAQ: KURA) kicked off on Friday, up 3.05% from the previous trading day, before settling in for the closing price of $20.32. Over the past 52 weeks, KURA has traded in a range of $7.41-$24.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -21.66%. With a float of $64.74 million, this company’s outstanding shares have now reached $74.35 million.
In an organization with 142 employees, it is important to assess its efficiency.
Kura Oncology Inc (KURA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kura Oncology Inc is 15.02%, while institutional ownership is 93.38%. The most recent insider transaction that took place on May 20 ’24, was worth 57,916. In this transaction Chief Legal Officer of this company sold 2,615 shares at a rate of $22.15, taking the stock ownership to the 68,979 shares. Before that another transaction happened on Jan 30 ’24, when Company’s Chief Medical Officer sold 4,825 for $21.55, making the entire transaction worth $103,980. This insider now owns 38,817 shares in total.
Kura Oncology Inc (KURA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.53 earnings per share (EPS), higher than consensus estimate (set at -0.55) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.93% during the next five years compared to -3.94% drop over the previous five years of trading.
Kura Oncology Inc (NASDAQ: KURA) Trading Performance Indicators
Take a look at Kura Oncology Inc’s (KURA) current performance indicators. Last quarter, stock had a quick ratio of 16.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -2.70 in one year’s time.
Technical Analysis of Kura Oncology Inc (KURA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.98 million. That was inferior than the volume of 1.11 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 28.12%. Additionally, its Average True Range was 1.05.
During the past 100 days, Kura Oncology Inc’s (KURA) raw stochastic average was set at 56.23%, which indicates a significant increase from 46.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.99% in the past 14 days, which was lower than the 47.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.55, while its 200-day Moving Average is $15.83. However, in the short run, Kura Oncology Inc’s stock first resistance to watch stands at $21.34. Second resistance stands at $21.74. The third major resistance level sits at $22.22. If the price goes on to break the first support level at $20.46, it is likely to go to the next support level at $19.98. Assuming the price breaks the second support level, the third support level stands at $19.58.
Kura Oncology Inc (NASDAQ: KURA) Key Stats
The company with the Market Capitalisation of 1.60 billion has total of 76,181K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -152,630 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -49,530 K.
